| ERGOLOID MESYLATE
Classifications: alpha-adrenergic antagonist; ergot alkaloid; Therapeutic: antidementia
Prototype: Ergotamine tartrate
Pregnancy Category: X
0.5 mg, 1 mg sublingual tablets; 1 mg tablets; 1 mg/mL oral liquid
Produces peripheral vasodilation primarily by central action and may cause slight reduction in BP and heart rate. Relieves
symptoms of cerebral arteriosclerosis.
Some improvements in Alzheimer's dementia symptoms, possibly by increasing cerebral metabolism with consequent increase in
blood flow. Improvement may not be apparent until after 34 wk of therapy.
Senile dementia of Alzheimer type.
Acute or chronic psychosis; hypersensitivity to ergoloid; pregnancy (category X), lactation.
Acute intermittent porphyria; elderly; hepatic disease; hypotension; bradycardia.
Route & Dosage
|Senile Dementia of Alzheimer Type
Adult: PO 1 mg t.i.d.; doses up to 4.512 mg/d have been used
- Instruct patient to allow sublingual (SL) tablet to dissolve under tongue and not to drink, eat, or smoke while tablet is
in place. Do not crush SL tablets.
- Store in tightly closed container.
Adverse Effects (≥1%)Body as a Whole:
Mostly dose related. CV:
Orthostatic hypotension, dizziness or light-headedness, flushing, sinus bradycardia. Special Senses:
Blurred vision, nasal stuffiness, increased nasopharyngeal secretions. GI:
Sublingual irritation, anorexia, stomach cramps, transient nausea and vomiting, heartburn. Skin:
Skin rash. CNS:
Drowsiness, headache. Other:
Precipitation of acute intermittent porphyria.
No clinically significant interactions established.
Incompletely from GI tract; 50% reaches systemic circulation. Peak:
1.53 h. Metabolism:
Undergoes rapid first-pass metabolism
in liver. Elimination:
Primarily in feces. Half-Life:
Assessment & Drug Effects
- Establish baseline values of BP and pulse; check at regular intervals throughout therapy.
- Report to physician sinus bradycardia (40 bpm); has been reported in patients receiving 1.5 mg doses. Pulse rate usually returns
to normal within 2 d after drug is discontinued.
- Withdraw drug permanently if marked bradycardia or hypotension occurs.
Patient & Family Education
- Make position changes slowly, particularly from recumbent to upright posture, and move ankles and feet for a few minutes before